Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Preoperative dexamethasone palmitate to prevent nausea and vomiting after open surgery

Official title: Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Open Surgery

Run by Beijing Tiantan Hospital · NCT06997419 · Data updated 2026-11-12

This tests whether giving a long-acting steroid called dexamethasone palmitate before open surgery can reduce postoperative nausea and vomiting in adults aged 18–65.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment500 (estimated)
SponsorBeijing Tiantan Hospital
Academic / other
Locations1 site (Beijing)
StatusRecruiting
StartedJuly 1, 2025
Main results expectedNovember 30, 2026
Study endsDecember 31, 2026
Registry record updatedSeptember 23, 2025
Trial IDNCT06997419 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–65 undergoing elective open spinal, chest, or abdominal surgery under general anesthesia who can give informed consent and are not pregnant or breastfeeding.

Probably not a fit

People allergic to dexamethasone, those who used systemic glucocorticoids within three months, or those with uncontrolled diabetes, severe heart/liver/kidney disease, active infection, systemic rheumatic disease, or pregnancy/breastfeeding are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Dexamethasone palmitate is a long-acting formulation that may provide prolonged anti-inflammatory and antiemetic effects compared with standard dexamethasone. In this interventional comparison, adults undergoing elective open spinal, chest, or abdominal surgery under general anesthesia receive preoperative dexamethasone palmitate or standard dexamethasone and are followed for postoperative nausea and vomiting and safety outcomes. The protocol excludes patients with recent systemic glucocorticoid use, severe cardiac/hepatic/renal or systemic rheumatic disease, uncontrolled diabetes, active infection, cognitive impairment or severe mental illness, and pregnant or breastfeeding individuals. Outcomes include incidence of PONV in the early postoperative period (including within 24 hours) and adverse events related to steroid exposure.

Why it matters

Potential benefit: If successful, it may offer longer-lasting prevention of postoperative nausea and vomiting with fewer side effects than standard dexamethasone.

How similar studies have gone: Standard dexamethasone is established to reduce PONV, but dexamethasone palmitate has been less studied for this indication and represents a relatively novel longer‑acting approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged 18 to 65 years;
* Providing written informed consent;
* Perform elective open surgery (Spinal surgery, open chest surgery, open abdominal surgery) undergoing general anesthesia.

Exclusion Criteria:

* Known to be allergic to dexamethasone;
* Any systemic glucocorticoids within 3 months before trial entry;
* History of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al);
* Cognitive impairment or severe mental illness;
* Uncontrolled diabetes or infectious diseases;
* Pregnancy or breastfeeding.

Where it's running

  • Fang Luo
    Beijing, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.